Yousif Capital Management LLC Trims Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Yousif Capital Management LLC reduced its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 11.3% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 12,487 shares of the biopharmaceutical company’s stock after selling 1,584 shares during the quarter. Yousif Capital Management LLC’s holdings in Regeneron Pharmaceuticals were worth $10,967,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of the company. Annis Gardner Whiting Capital Advisors LLC purchased a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at $26,000. Fortitude Family Office LLC purchased a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at $31,000. MCF Advisors LLC increased its holdings in shares of Regeneron Pharmaceuticals by 50.0% in the 4th quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 12 shares during the period. Criterion Capital Advisors LLC purchased a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at $37,000. Finally, Sutton Wealth Advisors Inc. increased its holdings in shares of Regeneron Pharmaceuticals by 38.2% in the 3rd quarter. Sutton Wealth Advisors Inc. now owns 47 shares of the biopharmaceutical company’s stock valued at $39,000 after acquiring an additional 13 shares during the period. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts recently weighed in on REGN shares. Sanford C. Bernstein started coverage on Regeneron Pharmaceuticals in a research note on Tuesday, March 12th. They set an “outperform” rating and a $1,125.00 target price on the stock. Bank of America boosted their target price on Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the stock an “underperform” rating in a research note on Friday, April 12th. Morgan Stanley boosted their target price on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 13th. UBS Group lifted their price target on Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the stock a “buy” rating in a research report on Wednesday, April 17th. Finally, Truist Financial reissued a “buy” rating and issued a $1,135.00 price objective on shares of Regeneron Pharmaceuticals in a report on Wednesday, April 3rd. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $977.77.

Insiders Place Their Bets

In other news, EVP Andrew J. Murphy sold 5,783 shares of the company’s stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $956.47, for a total value of $5,531,266.01. Following the sale, the executive vice president now directly owns 48,306 shares in the company, valued at $46,203,239.82. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $982.05, for a total value of $98,205.00. Following the completion of the transaction, the director now directly owns 18,282 shares in the company, valued at $17,953,838.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Andrew J. Murphy sold 5,783 shares of the company’s stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $956.47, for a total value of $5,531,266.01. Following the completion of the transaction, the executive vice president now owns 48,306 shares of the company’s stock, valued at $46,203,239.82. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 11,022 shares of company stock worth $10,552,991. 8.83% of the stock is owned by corporate insiders.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ:REGN traded down $0.78 during trading on Wednesday, reaching $906.54. The company had a trading volume of 368,025 shares, compared to its average volume of 488,088. The firm has a market capitalization of $99.50 billion, a price-to-earnings ratio of 26.17, a price-to-earnings-growth ratio of 2.59 and a beta of 0.11. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.69 and a quick ratio of 4.94. The stock’s fifty day moving average price is $951.41 and its 200 day moving average price is $893.20. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $684.80 and a fifty-two week high of $998.33.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share for the quarter, beating analysts’ consensus estimates of $10.73 by $1.13. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. The firm had revenue of $3.43 billion for the quarter, compared to the consensus estimate of $3.29 billion. During the same period in the previous year, the business earned $10.96 earnings per share. The company’s revenue for the quarter was up .6% compared to the same quarter last year. As a group, equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 38.8 EPS for the current year.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.